Research (R&D) Industry Analysis
Welcome to the Research & Development sector within Pharma & Healthcare. In this segment you will find reports on Clinical Trials and Company Pipeline reports.
RSS
previous
| PHARMACEUTICAL RESEARCH (France) - Industry Report (PLF01336) Plimsoll's PHARMACEUTICAL RESEARCH (France) analysis is the most definitive and accurate study of the PHARMACEUTICAL RESEARCH (France) sector in 2013. The report (compiled in French language) is split into two sections... | May 2013 | £505€599$786 |
| MEDICAL LABORATORIES (France) - Industry Report (PLF01670) Plimsoll's MEDICAL LABORATORIES (France) analysis is the most definitive and accurate study of the MEDICAL LABORATORIES (France) sector in 2013. The report (compiled in French language) is split into two sections... | May 2013 | £505€599$786 |
| SCIENTIFIC RESEARCH & DEVELOPMENT (France) - Industry Report (PLF01420) Plimsoll's SCIENTIFIC RESEARCH & DEVELOPMENT (France) analysis is the most definitive and accurate study of the SCIENTIFIC RESEARCH & DEVELOPMENT (France) sector in 2013. The report (compiled in French language) is... | May 2013 | £505€599$786 |
| Recherches Pharmaceutiques (PLF00378) Analyse des performances des sociétés françaisesL'étude de portefeuille Plimsoll RECHERCHES PHARMACEUTIQUES - vous apporte une analyse détaillée et à jour des 255 sociétés opérant sur le marché. Cette étude est idéale pour toute personne qui... | May 2013 | £505€599$786 |
| CONTRACT RESEARCH ORGANIZATION(Clinical Research) (France) - Industry Report (PLF01066) Plimsoll's CONTRACT RESEARCH ORGANIZATION (Clinical Research) (France) analysis is the most definitive and accurate study of the CONTRACT RESEARCH ORGANIZATION (Clinical Research) (France) sector in 2013. The report (compiled in French... | May 2013 | £505€599$786 |
| Recherche développement scientifique (PLF00456) Analyse des performances des sociétés françaisesL'étude de portefeuille Plimsoll - RECHERCHE-DEVELOPPEMENT SCIENTIFIQUE - vous apporte une analyse détaillée et à jour des 411 sociétés opérant sur le marché. Cette étude est idéale pour toute... | May 2013 | £505€599$786 |
| Medical & Scientific Research (Global) - Industry Report (PMW08701) Plimsoll's Medical & Scientific Research (Global) analysis is the most definitive and accurate study of the Medical & Scientific Research (Global) sector in 2013. The report is split into... | May 2013 | £950€1,125$1,479 |
| Medical & Scientific Research (European) - Industry Report (PMW08700) Plimsoll's Medical & Scientific Research (European) analysis is the most definitive and accurate study of the Medical & Scientific Research (European) sector in 2013. The report is split into... | May 2013 | £800€948$1,245 |
| Medical Research - Industry Report UK (PMS01256) Plimsoll Publishing's UK Medical Research Analysis provides a detailed overview of the UK Medical Research market and delivers a comprehensive individual analysis on the top 110 companies, including MERCK SHARP... | May 2013 | £350€415$545 |
| Adherens Junction Targeting in Oncology Drug Pipeline Update (BSK00575) 2013Analytical Tool - Protein Kinase Inhibitors in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in the drug development of protein kinase... | Apr 2013 | £1,265€1,499$1,969 |
| Leukemia Drug Pipeline Update (BSK00119) 2013The binding of Leptin to its receptor, LEPR induces various signaling modules such as JAK/STAT, RAS/RAF/MAPK, IRS/PI-3K and AMPK/ACC. There are today 246 companies plus partners developing 340 Leptin pathway targeting... | Apr 2013 | £1,265€1,499$1,969 |
| Hematological Cancers Drug Pipeline Update (BSK00118) 2013Aberrant activation of the Hedgehog pathway has been associated with a number of human malignancies including carcinoma of lung, esophagus, pancreas and prostate. There are today 55 companies plus partners developing... | Apr 2013 | £1,690€1,999$2,631 |
| Melanoma Drug Pipeline Update (BSK00123) 2013Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today 213 companies plus partners developing 314 lymphoma drugs in 434 developmental projects in cancer.... | Apr 2013 | £1,265€1,499$1,969 |
| Viral Carcinogenesis Drug Pipeline Update (BSK00601) 2013There is now much evidence that VEGFR-2 is the major mediator of VEGF-driven responses in endothelial cells and it is considered to be a crucial signal transducer in both physiologic... | Apr 2013 | £1,265€1,499$1,969 |
| Brain Cancer Drug Pipeline Update (BSK00114) 2013According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early,... | Apr 2013 | £1,265€1,499$1,969 |
| Colorectal Cancer Drug Pipeline Update (BSK00117) 2013Inflammatory immune response requires the recruitment of leukocytes to the site of inflammation upon foreign insult. Chemokines are small chemoattractant peptides that provide directional cues for the cell trafficking and... | Apr 2013 | £1,265€1,499$1,969 |
| Neuroendocrine Tumors Drug Pipeline Update (BSK00080) 2013The mammalian target of rapamycin (mTOR) is an intracellular kinase that controls the production of proteins through its regulation of translational machinery. mTOR-activated proteins promote several hallmarks of cancer such... | Apr 2013 | £845€999$1,315 |
| Immunotherapy in Oncology Drug Pipeline Update (BSK00049) 2013The IL-9 signaling pathway activates Jak/STAT and MAPK signaling modules. There are today 53 companies plus partners developing 51 IL-9 pathway targeting drugs in 216 developmental projects in cancer. In addition,... | Apr 2013 | £2,070€2,450$3,222 |
| Lung Cancer Drug Pipeline Update (BSK00121) 2013There are today 157 companies plus partners developing 188 drugs targeting liver cancer in development. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over... | Apr 2013 | £1,265€1,499$1,969 |
| Pancreatic Cancer Drug Pipeline Update (BSK00125) 2013p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes.... | Apr 2013 | £1,265€1,499$1,969 |
| Renal Cancer Drug Pipeline Update (BSK00127) 2013Receptor activator of nuclear factor-kappa B ligand (RANKL) is a member of tumor necrosis factor (TNF) superfamily. It binds to Receptor activator of NF-kB (RANK) and plays a major role... | Apr 2013 | £1,265€1,499$1,969 |
| Lymphoma Drug Pipeline Update (BSK00122) 2013Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two... | Apr 2013 | £1,265€1,499$1,969 |
| Cancer Vaccines Drug Pipeline Update (BSK00085) 2013Treatments designed to target and destroy cancer stem cells may come to revolutionize how we treat cancer. This unique product covers both explicit cancer stem cell drug development and cancer... | Apr 2013 | £1,265€1,499$1,969 |
| Cancer Stem Cells Drug Pipeline Update (BSK00009) 2013There are today 155 companies plus partners developing 187 calcium signaling pathway targeting drugs in 724 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the... | Apr 2013 | £1,265€1,499$1,969 |
| Ovarian Cancer Drug Pipeline Update (BSK00124) 2013Nucleic acid therapies in oncology includes: Gene Therapy, DNA vaccine, Other DNA technologies, RNA Interference (RNAi), Small interfering RNA (siRNA), Antisense RNA and Ribozymes. There are today 221 companies plus partners... | Apr 2013 | £1,265€1,499$1,969 |
